VRTX — Vertex Pharmaceuticals (Stock)

Price: $542.62 · 1 day: -0.81% · 5 days: +0.02% · 1 month: +11.83% · YTD: +19.69%
As of 2026-11-12 21:00 UTC.

52-week range: $412.27 – $568.67 (currently at 83% of the range).

The brief

VRTX is in an uptrend, momentum firm. $550 is the level overhead; $531.78 the first support below.

5 of 6 technical checks lean bullish.

TrendUptrend · above 50-day & 200-day
MomentumRSI 55.0 · MACD bullish
Trend strengthADX 14.6 · weak or range
Location+3.8% vs 50-day MA
52-week range-3% from high · +29% from low
VolatilityATR 18.54 · ~3.4%/day

Key levels

LevelTypeDistance
$550.0 (resistance)round1.36%
$557.97 (resistance)swing zone2.83%
$600.0 (resistance)round10.57%
$531.78 (support)swing zone-2.0%
$522.75 (support)sma 50-3.66%
$505.9 (support)swing zone-6.77%

Indicators

RSI (14)54.97MACD8.5174
ADX (14)14.6ATR (14)18.54
50-day average$522.75200-day average$483.03

Next earnings: 2026-11-02. VRTX earnings date, time and past reactions.

Vertex Pharmaceuticals (VRTX) stock analysis, November 3, 2026: Uptrend intact after earnings dip, but upside math thin

Report of 2026-11-03.

Vertex Pharmaceuticals (VRTX) fell 3.5% to $533.64 on November 3, 2026, the session after a third-quarter report that matched earnings expectations, beat on revenue and lifted full-year guidance. The drop looks like a market digesting a good-not-great print after a run to a 52-week high, not a broken story. The weekly uptrend is intact and the balance of evidence leans positive, with medium conviction, though the upside math from here is thin.

Why it matters

The quarter was solid without being surprising. Revenue came in at $3.44 billion against a $3.41 billion consensus, up 12% from a year earlier, while adjusted earnings of $4.76 per share matched estimates exactly, Investing.com reported. Alyftrek, Casgevy and Journavx together produced more than $2 billion in the first nine months. Management raised 2026 revenue guidance to $13.15 billion–$13.25 billion from $13.1 billion–$13.2 billion, and that range includes $40 million–$50 million expected from Palsonify after the September Crinetics acquisition.

That detail explains much of the reaction. A raise that is roughly the size of an acquired product's contribution says little new about the core business, and Investing.com notes the new midpoint sat 0.6% short of a comparison figure. GAAP profit also fell to $653.6 million, or $2.56 per share, per Morningstar. Meanwhile the stock had gained 5.7% over the past month and closed at $558.88 on October 30, its 52-week high, so a clean beat was needed to extend the move. The shares now sit 4.5% below that peak. Volume on the drop ran 9.3% above its 20-day average, firm but not panicked. One caution: the market rose 0.2% and the healthcare sector fell 0.2% the same day, so the news explains the direction of the drop better than its full size.

Over five days the picture is mostly about the sector. VRTX rose 2.4%, the S&P 500 fell 2.1% and the healthcare ETF XLV gained 2.8%. The stock beat the market comfortably but trailed its sector by 0.4 points, so healthcare strength did the work, not anything particular to Vertex. The 50-day comparison is the same story in two halves: VRTX leads the S&P 500 by 3.8% but lags XLV by 4.5%.

The argument about VRTX is mostly between constructive and neutral voices; no sharply negative article turned up in this batch. On the positive side, TD Cowen named seven biotech stocks as fourth-quarter top picks, citing solid fundamentals after a pullback from August highs, and a Motley Fool comparison with AbbVie came out favorable. The cooler view, in a Motley Fool piece against Amgen, frames Vertex as steady drug revenue rather than scale. The sceptical case really lives in the analyst spread: 28 analysts rate the stock a buy on average, with price targets from $350 to $725 and a mean of $576.29. At $533.64 the stock trades 7.4% below that mean, a cushion that holds only if the launches keep growing.

What the evidence says

The long-term thesis is intact. Price is above its 40-week average and well above the 200-day average at $480.25, the stock is up 25.9% over six months and 17.7% year to date, and it sits 30.3% above its 52-week low of $409.47. The phase is a pullback inside an uptrend, taking place after a run to a high rather than after a failure.

For the next 2–6 weeks the balance of evidence leans positive, with medium conviction: 2 of 4 points. The daily trend runs with the weekly uptrend, the stock leads the S&P 500 over 50 days, and the 50-day average at $523.04 is rising underneath the price. RSI at 62.6 shows room to move without being stretched. Conviction is not higher because only half the evidence lines up.

The strongest case against is the lag behind its own sector, 4.5% over 50 days, which says money is choosing other healthcare names. The price is also only $1.86 above the $531.78 support zone after a 3.5% one-day drop, and the nearest upside target offers little reward. It does not tip the balance because the weekly trend is still up and nothing has closed below the structure yet, but it is why the reading stops at medium.

Levels that matter

The structure holds above $531.78, a swing zone, and the first crack would be a close below it. The trend itself ends below $523.04, the 50-day average, where the stock would lose the line that has defined its advance. Below that, the next supports are $505.90, the $500 round number and $497.20.

The breakout level is a daily close above $550.00 on volume above its 20-day average, the first sign buyers are back after the earnings drop. From $550 the nearest target is the $557.97 swing zone, just under the October 30 peak, with $600 as the next round-number resistance. A stop at $527.30, a quarter of an ATR under $531.78, puts the reward-to-risk at 0.4 to 1. The math does not reach 3 to 1; it would need a target far above the nearest resistance, or a trigger much closer to the stop.

What would change the picture

A weekly close below $523.04, the 50-day average, would change the picture, because it would put the stock under the line that has carried the advance and turn this pullback into a trend break. The non-price fact that would do it is a cut to the $13.15 billion–$13.25 billion revenue guidance, which would suggest the launches of Alyftrek, Casgevy and Journavx are not carrying the growth the market is paying for.

What to watch

Latest VRTX news

Explore more

Interactive VRTX chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs